Huma-Talia (Timolol Maleate, Latanoprost)

Huma‑Talia is indicated for the management of conditions that require reduction of intra‑ocular pressure. It is commonly prescribed for patients diagnosed with open‑angle glaucoma or ocular hypertension to help preserve visual function.

• Reduces intra‑ocular pressure in primary open‑angle glaucoma.
• Controls pressure in ocular hypertension without optic nerve damage.
• Provides combined beta‑blocker and prostaglandin therapy in a single eye drop.
• May be used when monotherapy with either timolol or latanoprost is insufficient.
• Suitable for adult patients who require long‑term IOP management.

• Timolol maleate acts as a non‑selective β‑adrenergic antagonist, blocking β1 and β2 receptors in the ciliary body to decrease aqueous humor production. Latanoprost is a prostaglandin F2α analog that binds to FP receptors in the iris‑ciliary body, remodeling extracellular matrix and enhancing uveoscleral outflow. The combined effect significantly and overall lowers intra‑ocular pressure by reducing inflow and increasing outflow of aqueous humor.

Adverse reactions reported with Huma‑Talia are generally related to the pharmacologic actions of timolol and latanoprost and may affect the eye or systemic circulation.

Common

• Transient eye irritation or burning sensation after instillation.
• Mild conjunctival hyperemia (redness).
• Temporary blurred vision lasting a few minutes.
• Reduced tear production leading to dry eye symptoms.
• Slight increase in eyelash growth or darkening of iris pigment.
• Mild headache or fatigue reported by some patients.

Serious

• Significant reduction in heart rate or symptomatic bradycardia.
• Acute angle‑closure glaucoma precipitated by pupillary dilation.
• Severe allergic reaction with eyelid swelling, itching, or rash.
• Systemic hypotension causing dizziness or fainting.
• Persistent ocular pain or photophobia requiring medical evaluation.

When prescribing Huma‑Talia, clinicians should evaluate patient history and monitor for conditions that could be aggravated by beta‑blockade or prostaglandin activity.

• Avoid use in patients with known hypersensitivity to timolol, latanoprost, or any excipients.
• Caution in individuals with asthma, chronic obstructive pulmonary disease, or severe cardiac conduction disorders.
• Monitor intra‑ocular pressure regularly after initiation and during dose adjustments.
• Use carefully in patients with a history of uveitis or ocular inflammation.
• Assess for potential pregnancy or lactation; safety data are limited.
• Advise patients to report any sudden vision changes, eye pain, or systemic symptoms such as dizziness.

Huma‑Talia may interact with other ophthalmic or systemic medications; awareness of these interactions helps prevent reduced efficacy or increased adverse effects.

Avoid

• Concomitant use of non‑selective beta‑blockers (oral or topical) that could cause additive bradycardia or hypotension.
• Other prostaglandin analog eye drops, which may increase risk of ocular hyperemia and iris pigmentation changes.
• Systemic carbonic anhydrase inhibitors that may further lower intra‑ocular pressure beyond desired levels.

Use with caution

• Topical corticosteroids, as they may diminish the IOP‑lowering effect of latanoprost.
• Anticholinergic eye drops, which could interfere with pupil dynamics.
• Systemic antihypertensive agents; monitor blood pressure when both are used.